I. Eder

发表

Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours

H. Klocker, G. Bartsch, F. Frauscher, 2006, The Journal of Steroid Biochemistry and Molecular Biology.

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

H. Klocker, G. Bartsch, W. Horninger, 1998, Cancer research.

Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.

H. Klocker, I. Eder, Lin-lin Yang, 2011, Urology.

Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.

H. Klocker, G. Bartsch, P. Hååg, 2005, Future oncology.

Journal of Steroid Biochemistry and Molecular Biology Novel Therapeutic Approaches for the Treatment of Castration-resistant Prostate Cancer

H. Klocker, W. Horninger, F. Aigner, 2022 .

Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer.

H. Klocker, I. Eder, I. Heidegger, 2020, Urologic oncology.

Photodynamic Diagnosis with 5–Aminolevulinic Acid in the Treatment of Secondary Urethral Tumors: First in vitro and in vivo Results

H. Klocker, G. Bartsch, A. Stenzl, 2001, European Urology.

Oxidative phosphorylation and mitochondrial function differ between human prostate tissue and cultured cells

H. Klocker, G. Schäfer, I. Eder, 2016, The FEBS journal.

Long‐term androgen‐ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells

H. Klocker, G. Bartsch, I. Eder, 2004, The Prostate.

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer

H. Klocker, W. Horninger, I. Eder, 2021, Biomedicines.

Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.

H. Klocker, G. Bartsch, M. Cronauer, 1996, The Journal of urology.

Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas.

H. Klocker, G. Bartsch, M. Cronauer, 1997, British Journal of Cancer.

Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate

H. Klocker, G. Bartsch, M. Cronauer, 1997, The Prostate.

Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen Bicalutamide (Casodex) in a New Prostate Cancer Model

H. Klocker, G. Bartsch, J. Hoffmann, 2000, Urologia Internationalis.

Enhanced Inhibition of Prostate Tumor Growth by Dual Targeting the Androgen Receptor and the Regulatory Subunit Type Iα of Protein Kinase A in Vivo

H. Klocker, G. Schäfer, I. Eder, 2013, International journal of molecular sciences.

Akacid Medical Formulation Induces Apoptosis in Myeloid and Lymphatic Leukemic Cell Lines In Vitro and In Vivo

M. Steurer, C. Salvador, I. Eder, 2015, PloS one.

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

H. Klocker, G. Bartsch, D. Zopf, 2002, Cancer Gene Therapy.

SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent manner

M. Rudnicki, I. Eder, M. Puhr, 2013, Laboratory Investigation.

p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer

T. Furlan, G. Schäfer, I. Eder, 2020, Endocrine-related cancer.

A reliable system for the culture of human prostatic cells

H. Klocker, G. Bartsch, M. Cronauer, 1997, In Vitro Cellular & Developmental Biology - Animal.

H-CRRETAWAC-OH, a Lead Structure for the Development of Radiotracer Targeting Integrin α 5 β 1?

I. Eder, P. Gmeiner, I. Virgolini, 2014, BioMed research international.

Expression of androgen receptor coregulatory proteins in prostate cancer and stromal‐cell culture models

H. Klocker, G. Bartsch, I. Eder, 2000, The Prostate.

Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1.

H. Klocker, M. Cronauer, C. Marth, 1999, The American journal of pathology.

Reconstruction of the lower urinary tract using autologous muscle transfer and cell seeding: current status and future perspectives

H. Klocker, G. Bartsch, F. Frauscher, 2000, World Journal of Urology.

Mechanism of Androgen Receptor Activation and Possible Implications for Chemoprevention Trials

H. Klocker, G. Bartsch, I. Eder, 1999, European Urology.

Androgen Receptor Function in Prostate Cancer Progression

H. Klocker, G. Bartsch, I. Eder, 2007 .

Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic

H. Klocker, G. Bartsch, I. Eder, 2001, European Urology.

Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.

G Bartsch, H. Klocker, G. Bartsch, 1999, Cancer research.

Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides

H. Klocker, G. Bartsch, I. Eder, 2000, Cancer Gene Therapy.

Videoimaging of prostatic stromal‐cell contraction: An in vitro model for studying drug effects

H. Klocker, G. Bartsch, I. Eder, 1998, The Prostate.

595: Targeting Androgen Receptor in Hormone-Independent Cancer: Growth Inhibition and Induction of Apoptosis through Down Regulation of the Androgen Receptor with Small Interference RNA

H. Klocker, G. Bartsch, P. Hååg, 2004 .

Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells

H. Klocker, G. Bartsch, S. Mousses, 2003, Molecular carcinogenesis.

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer

H. Klocker, G. Kristiansen, D. Dietrich, 2013, Endocrine-related cancer.

Novel Experimental Therapeutic Approaches for Prostate Cancer

H. Klocker, I. Eder, Z. Culig, 2005 .

Calcineurin inhibitor‐induced complement system activation via ERK1/2 signalling is inhibited by SOCS‐3 in human renal tubule cells

M. Rudnicki, J. Troppmair, J. Guenther, 2018, European journal of immunology.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

H. Klocker, G. Schaefer, C. Ploner, 2017, Clinical Cancer Research.

In vitro model systems to study androgen receptor signaling in prostate cancer.

H. Klocker, I. Eder, M. Puhr, 2013, Endocrine-related cancer.

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer

H. Klocker, D. Schuster, H. Stuppner, 2020, Cancers.

Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate

H. Klocker, L. Kenner, Andrea Dueregger, 2015, PloS one.

Molecular effects of the isoflavonoid genistein in prostate cancer.

H. Klocker, G. Bartsch, A. Pelzer, 2005, Clinical prostate cancer.

Pathway in Prostate Cancer Cell Lines Kinase A Activator on the Mitogen-activated Protein Kinase Action of EGF , Insulin-like Growth Factor I , and a Protein Epidermal Growth Factor ( EGF ) Receptor Blockade Inhibits the Updated

H. Klocker, G. Bartsch, H. Grunicke, 1998 .

Epidermal Growth Factor ( EGF ) Receptor Blockade Inhibits the Action of EGF , Insulin-like Growth Factor I , and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines 1

H. Klocker, G. Bartsch, H. Grunicke, 1998 .

Age dependent apoptosis and loss of rhabdosphincter cells.

G Bartsch, M Steinlechner, M. Steinlechner, 2000, The Journal of urology.

Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP‐dependent protein kinase A

H. Klocker, G. Schäfer, I. Eder, 2010, International journal of cancer.

Gene therapy strategies in prostate cancer.

Georg Bartsch, Helmut Klocker, H. Klocker, 2005, Current gene therapy.

The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment

H. Klocker, Andrea Dueregger, I. Eder, 2014, Nutrients.

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo

H. Klocker, S. Geley, I. Eder, 2015, Molecular Endocrinology.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015, Oncotarget.

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells

H. Klocker, S. Geley, G. Schäfer, 2014, Oncotarget.

Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience

M. Rudnicki, Julia Kerschbaum, G. Mayer, 2019, Journal of clinical medicine.

3D Hanging Drop Culture to Establish Prostate Cancer Organoids.

I. Eder, T. Eder, 2017, Methods in molecular biology.

Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells

H. Klocker, I. Eder, H. Oberacher, 2018, International journal of molecular sciences.

Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture

H. Klocker, C. Ploner, I. Eder, 2016, International journal of molecular sciences.

Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells

H. Klocker, G. Bartsch, P. Hååg, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis

Helmut Klocker, Florian Pitterl, H. Klocker, 2020, Cell Communication and Signaling.

Selective culture conditions for different types of primary human bladder cells

H. Klocker, G. Bartsch, M. Cronauer, 2000, World Journal of Urology.

Long-Term Treatment with Simvastatin Leads to Reduced Migration Capacity of Prostate Cancer Cells

I. Eder, H. Neuwirt, M. Ladurner, 2022, Biomedicines.

Abstract 3: Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015 .

424: Overexpression of the Anti-Apoptotic Protein MCL-1 is an Early Event in Prostate Cancer

H. Klocker, G. Bartsch, G. Schaefer, 2004 .

Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.

H. Klocker, G. Bartsch, M. Cronauer, 1998, British Journal of Cancer.

Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer

H. Klocker, I. Eder, P. Massoner, 2010, British Journal of Cancer.

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

Martin R. Schneider, H. Klocker, G. Bartsch, 1999, British Journal of Cancer.

Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.

H. Klocker, G. Bartsch, M. Cronauer, 1996, The Journal of urology.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015, OncoTarget.

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo

H. Klocker, S. Geley, I. Eder, 2015, Molecular endocrinology.